Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Target

RELA

7 abstracts

Abstract
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years.
Org: Instituto Oncológico Fundación Arturo López Pérez and Department of Oncology, Instituto Nacional del Cáncer, Santiago, Chile, FAICIC Clinical Research, Veracruz, Mexico, Dermatology, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France,
Abstract
A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) subcutaneous (SC) vs NIVO + RELA FDC intravenous (IV) and NIVO SC vs NIVO IV in participants with melanoma.
Org: Alaska Oncology and Hematology, LLC., Bristol Myers Squibb Research,
Abstract
Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel).
Org: Department of Immunology, University of Pittsburgh,
Abstract
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC).
Org: Analysis Group Ltd.,
Abstract
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
Org: University of Texas MD Anderson Cancer Center, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University Duisburg-Essen, German Cancer Consortium, Instituto Oncológico Fundación Arturo López Pérez,
Abstract
Economic evaluation for the US of relatlimab and nivolumab (RELA+NIVO) versus nivolumab (NIVO) monotherapy in untreated advanced melanoma.
Org: University of Arizona, University of Arizona of Pharmacy, Department of Pharmacy Practice and Science,
Abstract
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
Org: University Hospital Essen, University Duisburg-Essen, West German Cancer Centre (WTZ), German Cancer Consortium (DKTK), Partner Site Munich, Partner Site Essen,